Država: Australija
Jezik: engleski
Izvor: Department of Health (Therapeutic Goods Administration)
mitozantrone hydrochloride, Quantity: 2.328 mg/mL (Equivalent: mitozantrone, Qty 2 mg/mL)
Baxter Healthcare Pty Ltd
Injection, concentrated
Excipient Ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections
Intravenous
1 vial
(S4) Prescription Only Medicine
For the treatment of *Locally advanced or metastatic carcinoma of the breast *Non-Hodgkin's lymphoma *Adult acute non-lymphocytic leukaemia (ANLL) *Chronic myelogenous leukaemia in blast crisis.
Visual Identification: Dark blue solution, free from visible particles; Container Type: Vial; Container Material: Glass; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2001-01-24
ONKOTRONE (mitozantrone) Consumer Medicine Information ONKOTRONE CMI 030505 Page 1 of 5 Baxter ONKOTRONE _Mitozantrone _ CONSUMER MEDICINE INFORMATION_ _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about ONKOTRONE. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking ONKOTRONE against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT ONKOTRONE IS USED FOR ONKOTRONE is used to treat various types of cancer. These include breast cancer, non- Hodgkin’s lymphoma (a cancer of the lymph glands), and leukaemia. ONKOTRONE belongs to a group of medicines called antineoplastic or cytotoxic medicines. You may also hear of these being called chemotherapy medicines. ONKOTRONE works by stopping cancer cells from growing and multiplying. Your doctor may have prescribed ONKOTRONE for another reason. Ask your doctor if you have any questions about why ONKOTRONE has been prescribed for you. ONKOTRONE may be used in combination with other medicines to treat cancer. ONKOTRONE is not addictive. This medicine is available only with a doctor’s prescription. BEFORE YOU ARE GIVEN ONKOTRONE _WHEN YOU MUST NOT BE GIVEN IT _ DO NOT HAVE ONKOTRONE IF YOU HAVE AN ALLERGY TO ONKOTRONE OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. Symptoms of an allergic reaction to ONKOTRONE may include: shortness of breath, wheezing, difficulty breathing or a tight feeling in your chest swelling of the face, lips, tongue or other parts of the body rash, itching, hives or flushed, red skin dizziness or light-headedness DO NOT HAVE ONKOTRONE IF YOU HAVE, OR HAVE HAD, ANY OF THE FOLLOWING MEDICAL CONDITIONS, UNLESS YOU HAVE FIRST DISCUSSED THIS WITH YOUR DOCTOR: severe liver problems_ _ heart pro Pročitajte cijeli dokument
Onkotrone (Mitozantrone hydrochloride) Concentrated Injection Version 1.1 1 of 13 AUSTRALIAN PRODUCT INFORMATION – ONKOTRONE (MITOZANTRONE HYDROCHLORIDE) CONCENTRATED INJECTION 1 NAME OF THE MEDICINE Mitozantrone hydrochloride 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Mitozantrone hydrochloride is a hygroscopic dark blue solid. Onkotrone concentrated Injection liquid has a pH of 3.0 - 4.5. One mL of the solution for injection contains 2.328 mg mitozantrone hydrochloride (equivalent to 2 mg mitozantrone). Excipients: sodium chloride, sodium acetate, glacial acetic acid and water for injections. 3 PHARMACEUTICAL FORM Onkotrone is a clear, dark blue concentrated Injection. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS Onkotrone is indicated for the treatment of: - locally advanced or metastatic carcinoma of the breast - Non-Hodgkin’s lymphoma - adult acute non-lymphocytic leukaemia (ANLL) - chronic myelogenous leukaemia in blast crisis 4.2 D OSE AND METHOD OF ADMINISTRATION The dose should be adjusted to each patient carefully. Doses greater than 140 mg/m 2 are not recommended, particularly as a single bolus injection. Such administrations have caused fatal overdose as a result of severe leucopenia and infection. USE IN CHILDREN: Experience in paediatric patients is limited INTRATHECAL USE: Safety for intrathecal use of mitozantrone has not yet been established. BREAST CANCER AND LYMPHOMA: Single-agent therapy: The recommended initial dosage for use as single agent is 14 mg/m 2 of body surface area, given as a single intravenous dose, which may be repeated at 21 days intervals. A lower initial dose (12 mg/m 2 or less) is recommended in patients with inadequate bone marrow reserves due to prior therapy or poor general condition. Dosage modification and timing of subsequent dosing should be determined by clinical judgement depending on the degree and duration of myelosuppression. If 21 day white blood cell and platelet Onkotrone (Mitozantrone hydrochloride) Concentrated Injection Version 1.1 2 of 13 counts Pročitajte cijeli dokument